B7S1, a Novel B7 Family Member that Negatively Regulates T Cell Activation

Prasad, Durbaka V. R.; Richards, Sabrina; Muoi, Xoi; Dong, Chen

doi:10.1016/s1074-7613(03)00147-x

Cited by 387 publications

(465 citation statements)

References 35 publications

Supporting

Mentioning

449

Contrasting

Order By: Relevance

“…Inhibitory B7 molecules have been demonstrated to be upregulated in different tumors, which may contribute to tumor immune evasion (Chen, 2004). B7-H4, a member of the B7 family, has been identified as a negative regulatory molecule on the cell membrane, which inhibits the proliferation and cytokine production of CD4+ T and CD8+ T cells (Prasad et al, 2003;Sica et al, 2003). In the tumor microenvironment, B7-H4 binds to an unknown receptor on the T cell surface, inhibiting tumor-specific T cell activation and proliferation.…”

Section: Discussionmentioning

confidence: 99%

B7-H4 Expression is Associated with Cancer Progression and Predicts Patient Survival in Human Thyroid Cancer

Zhu¹,

Chu²,

Yang³

et al. 2013

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

The B7-H4 coregulatory molecule is a member of the B7 family of molecules, which play a central role in the regulation of antigen-specific T cell-mediated immune responses. B7-H4, also referred to as B7x or B7S1, is a ligand within the B7 family that has been implicated as a negative regulator of T cell-mediated immunity. Robust B7-H4 protein expression is primarily restricted to activated T cells, B cells, dendritic cells, and monocytes.

show abstract

Section: Discussionmentioning

confidence: 99%

B7-H4 Expression is Associated with Cancer Progression and Predicts Patient Survival in Human Thyroid Cancer

Zhu¹,

Chu²,

Yang³

et al. 2013

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

show abstract

“…This duplication can be considered a relatively recent event in evolution, because the two pairs of IgV-IgC sequences are highly homologous. Recently, B7S1, a new B7 homologue, was described that, in being a GPI-linked molecule, also differs from the domain composition of the other known members of this family (20).…”

Section: Discussionmentioning

confidence: 99%

Molecular Characterization of Human 4Ig-B7-H3, a Member of the B7 Family with Four Ig-Like Domains

Schmitz

Majdic

Derdak

et al. 2004

The Journal of Immunology

231

245

View full text Add to dashboard Cite

In an effort to characterize molecules with immunoregulatory potential, we raised mAbs to human dendritic cells. We selected an Ab that recognizes a molecule that is induced on monocytes differentiated in vitro toward dendritic cells. Retroviral expression cloning identified this molecule as B7-H3, a member of the B7 family described recently. In contrast to an earlier report, in which B7-H3 was described as a molecule consisting of two Ig-like domains, our cDNA encoded a type I membrane protein with four Ig-like domains, and the molecule identified by us was therefore named 4Ig-B7-H3. mRNA analysis as well as Western blotting experiments performed by us did not reveal evidence for a small B7-H3. B7-H3 is not expressed on peripheral blood lymphocytes, monocytes, or granulocytes. Upon in vitro stimulation, the expression of B7-H3 is induced on T cells, B cells, and NK cells. A number of different approaches were used to investigate the function of human B7-H3. In contrast to an earlier report, our data do not support a costimulatory role of B7-H3 in anti-CD3-mediated activation of the TCR-complex resulting in T cell proliferation and IFN-γ production.

show abstract

“…Thus, CTLA-4 blockade via monoclonal antibody was proposed to stimulate T cell-mediated regression of tumors (4,5), which has led to numerous ongoing phase II/III clinical trials today. More recently, other B7-CD28 family members have been discovered, including B7-H1 (PD-L1) (6), B7-H3 (7), and B7x (B7-H4, B7S1) (8)(9)(10). Numerous human tumors have been reported to aberrantly express B7-H1, and several long-term investigations demonstrate that B7-H1 expression is associated with adverse pathologic features and poor survival (11)(12)(13)(14).…”

mentioning

confidence: 99%

“…B7-H3 protein expression has been described in numerous peripheral organs along with human malignancies of the lung, stomach, and prostate (16,20,21). B7x was discovered in 2003, and in contrast to B7-H3, has consistently demonstrated a negative costimulatory mechanism via inhibition of CD4 ϩ and CD8 ϩ T cell proliferation, cell-cycle progression, IL-2 production, and rendering tumor cells refractory to apoptosis (8)(9)(10)22). Similar to B7-H3, B7x is a type I transmembrane protein and has a yet-unidentified counterreceptor.…”

mentioning

confidence: 99%

B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome

Zang

Thompson²,

Al‐Ahmadie³

et al. 2007

Proc. Natl. Acad. Sci. U.S.A.

342

320

View full text Add to dashboard Cite

B7-H3 and B7x are recently discovered members of the B7-CD28 family thought to dampen peripheral immune responses via negative costimulation. We evaluated their potential expression in human prostate cancer using a large cohort of patients with 7 years of follow-up. We identified 823 patients with tissue available treated with radical prostatectomy between 1985 and 2003. Immunohistochemistry was performed on tissue microarray sections using anti-B7-H3 and -B7x. The percentage and intensity of immunoreactivity by tumor cells were blindly evaluated by two urological pathologists, and outcome analyses were conducted. Both B7-H3 and B7x were highly expressed; 93% and 99% of tumors had aberrant expression, respectively. The median percentage of tumor cells staining positive was 80% for each molecule. Strong intensity for B7-H3 and B7x was noted in 212 (26%) and 120 (15%) patients, respectively. Patients with strong intensity for B7-H3 and B7x were significantly more likely to have disease spread at time of surgery (P < 0.001 and P ‫؍‬ 0.005, respectively). Additionally, patients with strong intensity for B7-H3 and B7x were at significantly increased risk of clinical cancer recurrence (P < 0.001 and P ‫؍‬ 0.005) and cancer-specific death (P ‫؍‬ 0.004 and P ‫؍‬ 0.04, respectively). To our knowledge, we present the largest investigation of B7 family molecules in a human malignancy and a previously undescribed evaluation of B7x in prostate cancer. B7-H3 and B7x are abundantly expressed in prostate cancer and associated with disease spread and poor outcome. Given the proposed immune-inhibitory mechanisms of B7-H3 and B7x, these molecules represent attractive targets for therapeutic manipulation in prostate cancer.immune tolerance ͉ prostatic neoplasms ͉ treatment outcome ͉ biological tumor markers

show abstract

B7S1, a Novel B7 Family Member that Negatively Regulates T Cell Activation

Cited by 387 publications

References 35 publications

B7-H4 Expression is Associated with Cancer Progression and Predicts Patient Survival in Human Thyroid Cancer

B7-H4 Expression is Associated with Cancer Progression and Predicts Patient Survival in Human Thyroid Cancer

Molecular Characterization of Human 4Ig-B7-H3, a Member of the B7 Family with Four Ig-Like Domains

B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome

Contact Info

Product

Resources

About